Markets Analysts slash Neuronetics PTs but maintain buy ratings Analysts for Canaccord Genuity and BTIG slashed their prices targets for Neuronetics (NASDAQ:STIM) but maintained their “buy” ratings after the company reported that third quarter results missed consensus estimates... November 6, 2019